Circulating lung cancer biomarkers: From translational research to clinical practice
Tumor Biology · 19.03.2024 · 46 (s1) · S27-S33
DOI: 10.3233/tub-230012 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Tumor Biology, online erschienen am 28.10.2023. Verfasst von Xu Qian und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Laboratory, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine, Chinese Academy of Sciences, Hangzhou, China. Hauptthemen laut MEDLINE: Lung Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Fundamental studies on biomarkers as well as developed assays for their detection can provide valuable information facilitating clinical decisions. For patients with lung cancer, there are established circulating biomarkers such as serum progastrin-releasing peptide (ProGRP), neuron-specific enolase (NSE), squamous cell carcinoma antigen (SCC-Ag), carcinoembryonic antigen (CEA), and cytokeratin-19 fragment (CYFRA21-1). There are also molecular biomarkers for targeted therapy such as epidermal growth factor receptor (EGFR) gene, anaplastic lymphoma kinase (ALK) gene, KRAS gene, and BRAF gene. However, there is still an unmet need for biomarkers that can be used for early detection and predict treatment response and survival. In this review, we describe the lung cancer biomarkers that are currently being used in clinical practice. We also discuss emerging preclinical and clinical studies on new biomarkers such as omics-based biomarkers for their potential clinical use to detect, predict, or monitor subtypes of lung cancer. Additionally, between-method differences in tumor markers warrant further development and improvement of the standardization and harmonization for each assay.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Laboratory, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine, Chinese Academy of Sciences, Hangzhou, China.
- Department of Laboratory Medicine, the University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Zitieren
APA
Qian, X., & Meng, Q. H. (2024). Circulating lung cancer biomarkers: From translational research to clinical practice. Tumor Biology, 46(s1), S27-S33. https://doi.org/10.3233/tub-230012
Vancouver
Qian X, Meng QH. Circulating lung cancer biomarkers: From translational research to clinical practice. Tumor Biology. 2024;46(s1):S27-S33. doi:10.3233/tub-230012
BibTeX
@article{Qian2024,
author = {Qian, Xu and Meng, Qing-He},
title = {Circulating lung cancer biomarkers: From translational research to clinical practice},
journal = {Tumor Biology},
year = {2024},
volume = {46},
number = {s1},
pages = {S27--S33},
doi = {10.3233/tub-230012}
}
EUVIMED